Clinically, PCa progresses through distinct stages: localized PCa, confined to the prostate and amenable to curative treatments; non-metastatic castration-resistant prostate cancer, characterized by rising PSA despite castrate testosterone levels without detectable metastases; and metastatic disease, which includes hormone-sensitive and castration-resistant phases [2]. The gene discussed is KLK3; the disease is posterior cortical atrophy.